# EDGAR Filing Document

**Accession Number:** 0001810117
**File Stem:** 0001213900-25-107789
**Filing Date:** 2025-11
**Character Count:** 12331
**Document Hash:** ebb79d381a697a187be8a11a01797a8d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-107789.hdr.sgml**: 20251107

**ACCESSION NUMBER**: 0001213900-25-107789

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251107

**DATE AS OF CHANGE**: 20251107

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewcelX Ltd.
- **CENTRAL INDEX KEY:** 0001783036
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92065
- **FILM NUMBER:** 251464114

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **BUSINESS PHONE:** 41-41-618-80-00

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NLS Pharmaceutics Ltd.
- **DATE OF NAME CHANGE:** 20190719
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP
- **CENTRAL INDEX KEY:** 0001810117

**ORGANIZATION NAME:**
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** BOODENHIMER 24
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6200838
- **BUSINESS PHONE:** 00972546444183

**MAIL ADDRESS:**
- **STREET 1:** BOODENHIMER 24
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6200838

## Exhibit 99.1

**Exhibit 1**

**JOINT FILING AGREEMENT**

**PURSUANT TO RULE 13d-1(k)**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

---

| | | | |
|:---|:---|:---|:---|
| Date: November 7, 2025 |  |  |  |
|  | Clover Wolf Capital – Limited Partnership | Clover Wolf Capital – Limited Partnership | Clover Wolf Capital – Limited Partnership |
|  | By: | */s/ Adi Wolf* | */s/ Adi Wolf* |
|  |  | Name: | Adi Wolf |
|  |  | Title: | Managing Partner |

---

---

| | | |
|:---|:---|:---|
| Date: November 7, 2025 |  |  |
|  | Adi Wolf | Adi Wolf |
|  | By: | */s/ Adi Wolf* |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** NewcelX Ltd.

**Title of Class of Securities:** Common Shares

**CUSIP Number:** H5835A109

**Date of Event Which Requires Filing of this Statement:** 10/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Clover Wolf Capital - Limited Partnership | Names of Reporting Persons<br>Clover Wolf Capital - Limited Partnership |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>L3 | Citizenship or Place of Organization<br>L3 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>343120.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>343120.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>343120.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>343120.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>7.5% | Percent of Class Represented by Amount in Row (9)<br>7.5% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** (1) Consists of 343,120 common shares, par value CHF 0.05 of NewcelX Ltd. (the "Common Shares"). Ms. Adi Wolf has sole voting and dispositive power over the shares held by Clover Wolf Capital - Limited Partnership.

(2) Based on 4,558,378 Common Shares issued and outstanding as of October 31, 2025, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on October 29, 2025.

---

| 1. | Names of Reporting Persons<br>Adi Wolf | Names of Reporting Persons<br>Adi Wolf |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>L3 | Citizenship or Place of Organization<br>L3 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>343120.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>343120.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>343120.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>343120.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>7.5% | Percent of Class Represented by Amount in Row (9)<br>7.5% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** (1) Consists of 343,120 Common Shares. Ms. Adi Wolf has sole voting and dispositive power over the shares held by Clover Wolf Capital - Limited Partnership.

(2) Based on 4,558,378 Common Shares issued and outstanding as of October 31, 2025, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on October 29, 2025.

---

**Item 1(a). Name of Issuer:**
NewcelX Ltd.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
The Circle 6, Zurich, Switzerland 8058

**Item 2(a). Name of Person Filing:**
(1) Ms. Adi Wolf

(2) Clover Wolf Capital - Limited Partnership

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons." The statement is being filed on behalf of the Reporting Persons.

**Item 2(b). Address of Principal Business Office:**
The address of the Reporting Persons is:

24 Bodenheimer St.
Tel Aviv, 6200838, Israel

**Item 2(c). Citizenship:**
(3) Ms. Adi Wolf is a citizen of the State of Israel.

(4) Clover Wolf Capital - Limited Partnership is a partnership formed under the laws of the State of Israel.

**Item 2(d). Title of Class of Securities:**
Common Shares

**Item 2(e). CUSIP Number:**
H5835A109

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Each Reporting Person may be deemed to beneficially own 343,120 Common Shares. Ms. Adi Wolf has sole voting and dispositive power over the shares held by Clover Wolf Capital - Limited Partnership.

**(b) Percent of class:**

7.5%(1)
(1) Based on 4,558,378 Common Shares issued and outstanding as of October 31, 2025, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on October 29, 2025.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

0

**(ii) Shared power to vote or to direct the vote:**

343,120

**(iii) Sole power to dispose or to direct the disposition of:**

0

**(iv) Shared power to dispose or to direct the disposition of:**

343,120

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Clover Wolf Capital - Limited Partnership**

**Date:** 11/07/2025

**By:** /s/ Adi Wolf

**Name & Title:** Adi Wolf/ Managing Partner of Clover Wolf Capital - Limited Partnership

**Adi Wolf**

**Date:** 11/07/2025

**By:** /s/ Adi Wolf

**Name & Title:** Adi Wolf